“We are pondering the idea of an acquisition in Romania and our plans until 2015 involve inorganic growth. It is a rather risky plan under the current circumstances, so we have taken a wait-and-see approach. But this figure is not achievable just through organic growth,” said Cristina Garlasu, general manager of Dr. Reddy’s Laboratories Romania.

The company has been present on the Romanian market since 1995, when it recruited Cristina Garlasu for the position she currently holds. The company has products in areas such as gastroenterology, oncology, cardiovascular, and pain therapy, with its best-selling product being Omez (to treat diseases of the digestive tract).

More aggressive growth in Romania

A prospective acquisition of Dr. Reddy’s could target a product, a line of products or a small producer, but Garlasu said these plans have been put on hold by the unpredictable market conditions.

“We don’t have a budget for this acquisition, but intend for around 20% of 2015’s turnover to come from inorganic activities of any kind. We don’t manufacture in Romania at present. We have various talks for in-licensing [acquisition of permits of putting a product on the market or even acquisition of finished products] and potentially a manufacturing contract (production of drugs in the facilities of other producers who have excess capacity,” Garlasu added.

The company’s Romanian portfolio includes only prescription-based products, while in Europe the company has operations in the UK, Germany and Italy.

On the local market 70% of the company’s turnover is generated by gastroenterology drugs.

Garlasu says the company’s development plans for Romania are more aggressive than in other European countries because Romania remains attractive in the medium term through its growth potential.

“Europe is in a semi-stagnation phase in terms of the development of the pharmaceutical market. [Research company] IMS predicts growth of 2-3% at the most over the next five years. Romania, although it is unpredictable, has a very big chance of growth over the next few years, of 12-14%”

“No business is interesting in the absence of growth”

In the fiscal year that ended in March 2012, Dr. Reddy’s had sales of $18 million and growth of 9% in Romania, and for this fiscal year relies on growth generated mainly by the launch of four new products. In March 2013 the company hopes to reach turnover of $22 million.

“We are looking both at the turnover and at profitability. We have to do both. We expect to grow because no business is interesting in the absence of growth, but we expect to grow and make a profit,” Garlasu said.

(English version by Daniela Stoican)